Human Longevity and LEV Foundation: Pioneering Research Collaboration for Understanding Longevity

Human Longevity and LEV Foundation Collaboration

On March 25, 2026, Human Longevity, Inc. (HLI) and the LEV Foundation (LEVF) declared their partnership aimed at enhancing the understanding of human aging. This collaboration, led by the esteemed Natalie S. Coles-de Grey, represents a significant step forward in longevity research. By integrating HLI's AI-driven precision longevity platform with LEVF's mission, the research will delve into the blood samples of centenarians—those aged 100 and above—and supercentenarians aged 110 and older.

The core objective of this initiative is to address the fundamental question in biomedicine: why do individuals exhibit different aging rates? The insights gained from this research could lead to significant advancements in interventions aimed at delaying age-related decline and enhancing the quality of life in older populations. Dr. Coles-de Grey’s extensive expertise in supercentenarians empowers this project with exceptional potential to uncover the secrets to achieving a long and healthy life.

The Biological Treasure Trove of Longevity

Centenarians and supercentenarians represent unique biological resources, with their blood samples holding critical molecular and cellular information. This research will apply comprehensive multi-omic analyses involving genomics and proteomics to identify significant biomarkers and pathways that contribute to extraordinary longevity. Researchers aim to uncover the key molecular features that differentiate these remarkably long-lived individuals from the general population.

Moreover, the study will facilitate comparative analyses of exceptionally long-lived individuals with broader population cohorts, aiming to establish a foundational understanding for future studies in longevity science.

Dr. Wei-Wu He, Executive Chairman at HLI, emphasized the profound implications of this research, stating, "By applying our precision longevity platform to those who have achieved exceptional longevity, we can better grasp how to maintain health in late life for everyone. The knowledge we gain can significantly transform our approach to aging and age-related diseases."

Revolutionary Insights into Aging and Health

Dr. Aubrey de Grey, President and Chief Science Officer of LEVF, expressed his excitement about the collaboration, highlighting the potential to refine preventive measures for chronic conditions prevalent in older adults. He remarked, "There is so much to learn from our oldest citizens that will enhance the preventative medicine pioneered by HLI. This work beautifully complements LEVF's focus on various anti-aging interventions and is bound to save numerous lives in the future."

The study's findings may contribute to innovations in diagnostics, therapeutics, and preventive strategies aimed at extending healthspan across diverse populations globally, fostering healthier aging processes in later years.

About Human Longevity, Inc.

Founded in 2013, Human Longevity, Inc. stands at the forefront of biotechnology, integrating genomics, artificial intelligence, and advanced diagnostics to extend human healthspan. Through its Executive Health Program and multiple Longevity Programs, HLI delivers thorough, data-driven evaluations aimed at identifying and preemptively addressing diseases.

About LEV Foundation

Founded in 2022, LEV Foundation is a nonprofit organization based in California that champions research and initiatives focused on extending healthy human lifespans. Their flagship project, the "Robust Mouse Rejuvenation" study series, investigates various anti-aging methods' collective benefits.

This collaboration marks a new chapter in longevity science, with the potential to unlock the mysteries of aging and significantly improve health outcomes for populations worldwide.